# About CJC-1295 Clinic — An independent editorial reading room

> CJC-1295 Clinic is an independent editorial project that summarizes the peer-reviewed CJC-1295 research literature. We are not a clinic. We do not employ clinicians and we do not provide medical advice.

The word "clinic" in our domain is editorial framing: a position the publisher occupies relative to the literature, not a claim about services. Here is what that means in practice.

## What this publisher is

CJC-1295 Clinic is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295. Our work is editorial commentary on publicly available science. The published CJC-1295 record is small and finite — fewer than ten substantive peer-reviewed studies, one terminated Phase 2 trial, and a regulatory tail of FDA and WADA documents. We organize that record into a reading room: a hero band, a chronological research page, a research-context dosage summary, a frequently-asked-questions page, and a numbered reference list with DOIs and PubMed URLs.

The coastal-studio register of this site is deliberate. CJC-1295's pharmacokinetic story has a slow-tide quality — the DAC variant's covalent bond to circulating serum albumin produces a sustained GH and IGF-1 signal measured in days rather than minutes [3], and the regulatory chapter has unfolded in a similarly slow rhythm across two decades. A calm editorial atelier matches that pace better than a clinical-leaflet or marketing register would.

## What this publisher is not

We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. We do not operate a telehealth service, run a prescriber referral, or maintain a treatment protocol. The word "clinic" in our domain name is editorial framing — the same way "workshop," "observatory," or "reading room" might frame a publisher's posture toward a body of work — not a claim about services.

We do not invent staff. There is no fictional clinical team, no in-house pharmacist, no medical director. There is an editorial publisher and a research methodology. Where individual authorship is meaningful — for an investigative piece, say — it would be signed; the summary pages on this site are unsigned editorial work because they synthesize the published literature rather than report original findings.

## Editorial standards and sourcing

Every quantitative claim on this site is sourced to a peer-reviewed paper, a ClinicalTrials.gov record, an FDA briefing document, or a WADA standard. Citations are numbered inline as [N] markers and resolve to the [References](/references) page, which lists author names, journal, year, DOI, and primary-source URL for every entry.

We do not link to vendor sites, compounding-pharmacy retailers, or peptide-marketplace pages. We do not reproduce dosing schedules from non-peer-reviewed sources. We do not use competitor or product brand names — recombinant GH and approved GHRH analogs are referred to by their International Nonproprietary Names (e.g., tesamorelin) rather than by trade names. Where the published record contains an absence — no Phase 3 program, no peer-reviewed Phase 2 results, no long-term safety dataset — we name the absence rather than fill it with inference.

## Disclaimer

Nothing on this site constitutes medical advice. CJC-1295 is a research chemical with no approved human indication. It was not recommended for the Section 503A bulk drug substances list at either the October or December 2024 FDA Pharmacy Compounding Advisory Committee meetings, was removed from FDA Category 2 effective September 27, 2024 [14], and is prohibited at all times under WADA Section S2 for athletes subject to the Code [16]. This publisher is an editorial reading room. It does not manufacture, dispense, sell, or distribute any substance and is not affiliated with any vendor or compounding pharmacy.

---

An independent editorial digest of the peer-reviewed CJC-1295 literature — not a clinic, not a vendor, not clinical counsel.